JP2015513919A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015513919A5 JP2015513919A5 JP2015505732A JP2015505732A JP2015513919A5 JP 2015513919 A5 JP2015513919 A5 JP 2015513919A5 JP 2015505732 A JP2015505732 A JP 2015505732A JP 2015505732 A JP2015505732 A JP 2015505732A JP 2015513919 A5 JP2015513919 A5 JP 2015513919A5
- Authority
- JP
- Japan
- Prior art keywords
- pancreatic cancer
- cancer cell
- aptamer
- molecules
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 25
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 25
- 201000002528 pancreatic cancer Diseases 0.000 claims 25
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 25
- 210000004027 cell Anatomy 0.000 claims 18
- 108091023037 Aptamer Proteins 0.000 claims 14
- 229940124597 therapeutic agent Drugs 0.000 claims 11
- 239000003814 drug Substances 0.000 claims 10
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 3
- 239000000032 diagnostic agent Substances 0.000 claims 3
- 229940039227 diagnostic agent Drugs 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 208000009164 Islet Cell Adenoma Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 108091027967 Small hairpin RNA Proteins 0.000 claims 2
- 108020004459 Small interfering RNA Proteins 0.000 claims 2
- 239000012830 cancer therapeutic Substances 0.000 claims 2
- 201000000052 gastrinoma Diseases 0.000 claims 2
- 108020004999 messenger RNA Proteins 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 108091070501 miRNA Proteins 0.000 claims 2
- 239000002679 microRNA Substances 0.000 claims 2
- 239000002773 nucleotide Substances 0.000 claims 2
- 125000003729 nucleotide group Chemical group 0.000 claims 2
- 239000004055 small Interfering RNA Substances 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 206010068873 Adenosquamous cell carcinoma Diseases 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 208000007569 Giant Cell Tumors Diseases 0.000 claims 1
- 206010018404 Glucagonoma Diseases 0.000 claims 1
- 102000018697 Membrane Proteins Human genes 0.000 claims 1
- 108010052285 Membrane Proteins Proteins 0.000 claims 1
- 206010073150 Multiple endocrine neoplasia Type 1 Diseases 0.000 claims 1
- 206010041329 Somatostatinoma Diseases 0.000 claims 1
- 108010003205 Vasoactive Intestinal Peptide Proteins 0.000 claims 1
- 102400000015 Vasoactive intestinal peptide Human genes 0.000 claims 1
- 201000008629 Zollinger-Ellison syndrome Diseases 0.000 claims 1
- 208000006336 acinar cell carcinoma Diseases 0.000 claims 1
- 208000009956 adenocarcinoma Diseases 0.000 claims 1
- 201000008395 adenosquamous carcinoma Diseases 0.000 claims 1
- 239000002872 contrast media Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000000975 dye Substances 0.000 claims 1
- 239000003623 enhancer Substances 0.000 claims 1
- 208000015419 gastrin-producing neuroendocrine tumor Diseases 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 206010022498 insulinoma Diseases 0.000 claims 1
- 230000003834 intracellular effect Effects 0.000 claims 1
- VBUWHHLIZKOSMS-RIWXPGAOSA-N invicorp Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)C(C)C)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 VBUWHHLIZKOSMS-RIWXPGAOSA-N 0.000 claims 1
- 201000002529 islet cell tumor Diseases 0.000 claims 1
- 208000010492 mucinous cystadenocarcinoma Diseases 0.000 claims 1
- 208000022669 mucinous neoplasm Diseases 0.000 claims 1
- 239000002105 nanoparticle Substances 0.000 claims 1
- 208000021255 pancreatic insulinoma Diseases 0.000 claims 1
- 208000022102 pancreatic neuroendocrine neoplasm Diseases 0.000 claims 1
- 208000002820 pancreatoblastoma Diseases 0.000 claims 1
- 239000012857 radioactive material Substances 0.000 claims 1
- 208000011581 secondary neoplasm Diseases 0.000 claims 1
- 208000004548 serous cystadenocarcinoma Diseases 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 230000005945 translocation Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261622375P | 2012-04-10 | 2012-04-10 | |
| US61/622,375 | 2012-04-10 | ||
| PCT/US2013/031074 WO2013154735A1 (en) | 2012-04-10 | 2013-03-13 | Rna aptamers for therapeutic and diagnostic delivery to pancreatic cancer cells |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015513919A JP2015513919A (ja) | 2015-05-18 |
| JP2015513919A5 true JP2015513919A5 (https=) | 2016-04-28 |
Family
ID=49328023
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015505732A Pending JP2015513919A (ja) | 2012-04-10 | 2013-03-13 | 膵癌細胞への治療的送達および診断的送達のためのｒｎａアプタマー |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US9464293B2 (https=) |
| EP (1) | EP2836501B1 (https=) |
| JP (1) | JP2015513919A (https=) |
| AU (1) | AU2013246419A1 (https=) |
| CA (1) | CA2870288A1 (https=) |
| WO (1) | WO2013154735A1 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014071219A1 (en) | 2012-11-01 | 2014-05-08 | Factor Bioscience Inc. | Methods and products for expressing proteins in cells |
| WO2014144744A1 (en) | 2013-03-15 | 2014-09-18 | The Trustees Of Columbia University In The City Of New York | Aptamer methods and compositions |
| EP3024497B1 (en) * | 2013-07-26 | 2021-01-13 | University of Iowa Research Foundation | Methods and compositions for treating brain diseases |
| JP6313478B2 (ja) * | 2014-05-30 | 2018-04-18 | アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ | Ｍａｇｅ−ａ３ペプチド標的アプタマー及びその使用 |
| CN107106697B (zh) * | 2014-10-15 | 2021-06-18 | 希望之城 | Pdgfr rna适体 |
| US10550394B2 (en) | 2015-03-31 | 2020-02-04 | City Of Hope | Anti-cancer RNA aptamers |
| AU2016346269A1 (en) * | 2015-10-30 | 2018-05-24 | Tagcyx Biotechnologies | DNA aptamer binding to cancer cell |
| EP3416690A4 (en) * | 2016-02-19 | 2020-02-19 | City of Hope | SPECIFIC APTAMER |
| US11845938B2 (en) | 2016-03-31 | 2023-12-19 | City Of Hope | Aptamer compositions and the use thereof |
| WO2019033050A1 (en) * | 2017-08-11 | 2019-02-14 | City Of Hope | BISPECIFIC MOLECULE FOR BINDING TO ANTIGEN |
| WO2019033051A1 (en) | 2017-08-11 | 2019-02-14 | City Of Hope | RNA APTAMERS AGAINST THE TRANSFERRIN RECEPTOR (TFR) |
| PL3502552T3 (pl) * | 2017-12-21 | 2022-12-12 | Marelli Automotive Lighting Italy S.p.A. | Lampa pojazdu z częściami o różnych poziomach luminancji |
| US11225665B2 (en) | 2019-06-20 | 2022-01-18 | City Of Hope | P38 map kinase inhibitors |
| KR102294694B1 (ko) * | 2019-07-18 | 2021-08-30 | 국립암센터 | 신규한 dna 앱타머 및 이의 용도 |
| BR112023022439A2 (pt) | 2021-04-26 | 2023-12-26 | Celanese Eva Performance Polymers Llc | Dispositivo implantável para liberação sustentada de um composto de fármaco macromolecular |
| US20260002163A1 (en) | 2022-07-06 | 2026-01-01 | Molecular Axiom, Llc | Compositions and methods for treating pancreatic cancer |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030073207A1 (en) * | 1997-01-31 | 2003-04-17 | Saghir Akhtar | Enzymatic nucleic acid treatment of diseases or conditions related to levels of epidermal growth factor receptors |
| WO1999065928A2 (en) | 1998-06-19 | 1999-12-23 | Genzyme Corporation | Polynucleotide population isolated from non-metastatic and metastatic breast tumor tissues |
| US20030064946A1 (en) * | 2000-08-09 | 2003-04-03 | Mcswiggen James | Method and reagent for the inhibition of calcium activated chloride channel-1 (CLCA-1) |
| US7524630B2 (en) | 2002-04-22 | 2009-04-28 | University Of Florida Research Foundation, Inc. | Functionalized nanoparticles and methods of use |
| CA2868618C (en) * | 2002-10-16 | 2017-05-23 | Gen-Probe Incorporated | Compositions and methods for detecting west nile virus |
| US7655785B1 (en) * | 2002-11-14 | 2010-02-02 | Rosetta Genomics Ltd. | Bioinformatically detectable group of novel regulatory oligonucleotides and uses thereof |
| US20100254901A1 (en) * | 2005-07-28 | 2010-10-07 | Smith Cassandra L | Compositions comprising nucleic acid aptamers |
| WO2007128109A1 (en) * | 2006-05-04 | 2007-11-15 | University Health Network | Aptamers that recognize the carbohydrate n-acetylgalactosamine (galnac) |
| GB2437727B (en) | 2006-05-04 | 2011-04-20 | Univ Open | Aptamers directed to MUC1 |
| US20110052697A1 (en) | 2006-05-17 | 2011-03-03 | Gwangju Institute Of Science & Technology | Aptamer-Directed Drug Delivery |
| US20090169613A1 (en) * | 2007-11-09 | 2009-07-02 | Reznik Boris N | Targeting of tumor stem cells through selective silencing of boris expression |
| WO2009129465A2 (en) * | 2008-04-17 | 2009-10-22 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of xbp-1 gene |
| US8563711B2 (en) * | 2009-06-01 | 2013-10-22 | Sungkyunkwan University Foundation For Corporate Collaboration | Nucleic acid aptamer capable of binding specifically to pancreatic cancer cells or tissues and use thereof |
-
2013
- 2013-03-13 US US14/391,997 patent/US9464293B2/en active Active
- 2013-03-13 EP EP13775956.9A patent/EP2836501B1/en not_active Not-in-force
- 2013-03-13 JP JP2015505732A patent/JP2015513919A/ja active Pending
- 2013-03-13 CA CA2870288A patent/CA2870288A1/en not_active Abandoned
- 2013-03-13 WO PCT/US2013/031074 patent/WO2013154735A1/en not_active Ceased
- 2013-03-13 AU AU2013246419A patent/AU2013246419A1/en not_active Abandoned
-
2016
- 2016-03-28 US US15/082,621 patent/US20160201059A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015513919A5 (https=) | ||
| Yoon et al. | Targeted delivery of C/EBPα-saRNA by pancreatic ductal adenocarcinoma-specific RNA aptamers inhibits tumor growth in vivo | |
| Zhao et al. | Designing strategies of small-molecule compounds for modulating non-coding RNAs in cancer therapy | |
| Mao et al. | Nidogen 1‐enriched extracellular vesicles facilitate extrahepatic metastasis of liver cancer by activating pulmonary fibroblasts to secrete tumor necrosis factor receptor 1 | |
| Pomatto et al. | Improved loading of plasma-derived extracellular vesicles to encapsulate antitumor miRNAs | |
| Han et al. | Application and development of aptamer in cancer: from clinical diagnosis to cancer therapy | |
| Peng et al. | Aptamer-conjugated gold nanoparticles targeting epidermal growth factor receptor variant III for the treatment of glioblastoma | |
| Abdelaal et al. | A first-in-class fully modified version of miR-34a with outstanding stability, activity, and anti-tumor efficacy | |
| Su et al. | Pancreatic cancer cell exosome-mediated macrophage reprogramming and the role of microRNAs 155 and 125b2 transfection using nanoparticle delivery systems | |
| Kuai et al. | Circular bivalent aptamers enable in vivo stability and recognition | |
| Li et al. | Apoptosis and micro RNA aberrations in cancer | |
| Chen et al. | Inducible degradation of oncogenic nucleolin using an aptamer-based PROTAC | |
| Wang et al. | Pancreatic cancer: understanding and overcoming chemoresistance | |
| Mousavi et al. | Non-coding RNAs and glioblastoma: Insight into their roles in metastasis | |
| Li et al. | Targeting long noncoding RNA in glioma: a pathway perspective | |
| Tang et al. | MicroRNA-101 inhibits invasion and angiogenesis through targeting ITGA3 and its systemic delivery inhibits lung metastasis in nasopharyngeal carcinoma | |
| Leal et al. | MicroRNAs and cancer stem cells: therapeutic approaches and future perspectives | |
| Yan et al. | Delivery of anti-microRNA-21 by lung-targeted liposomes for pulmonary fibrosis treatment | |
| Xue et al. | MicroRNAs in cancer therapeutic response: Friend and foe | |
| Chai et al. | Micro RNA‐494 sensitizes colon cancer cells to fluorouracil through regulation of DPYD | |
| Han et al. | MicroRNA-34a suppresses aggressiveness of hepatocellular carcinoma by modulating E2F1, E2F3, and Caspase-3 | |
| Orellana et al. | Enhancing microRNA activity through increased endosomal release mediated by nigericin | |
| Li et al. | miR-122 inhibits hepatocarcinoma cell progression by targeting LMNB2 | |
| Huang et al. | microRNA biomarkers in colorectal cancer liver metastasis | |
| Tseng et al. | Metformin inhibits gastric cancer cell proliferation by regulation of a novel Loc100506691-CHAC1 axis |